Accessibility Menu
Lexeo Therapeutics logo

Lexeo Therapeutics(NASDAQ) LXEO

Market Cap$411.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-50%
5 YearN/A
1 Year+2%
1 Month+12%
Premium Feature
Moneyball Superscore
56/100
$4.99
-0.50%
-0.02Today
After hours$4.98-$0.00 (-0.10%)
Lexeo Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 5.012026-08-26
Lexeo Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.7%USD 5.372026-08-19
1 month+12.08%USD 4.472026-07-27
3 month-1.38%USD 5.082026-05-28
Year to date-49.55%USD 9.932025-12-31
1 year+2.45%USD 4.892025-08-26
Since inception-50.15%USD 10.052023-11-03

Lexeo Therapeutics Financials at a Glance

Market Cap

$411.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$87.27M

EPS (TTM)

-$1.16

P/E Ratio

-4.33

Dividend

$0.00

Beta (Volatility)

1.95 (High)

Price

$4.99

Volume

1,105,717.534

Open

$4.97

Previous Close

$4.99

Daily Range

$4.89 - $5.09

52-Week Range

$3.99 - $10.99

Estimated Earnings Date

Dec 14, 2026

LXEO News

Foolcom-Featured.png

Lexeo Reports Q2 Loss as Costs Jump 129%

Motley Fool Markets TeamAug 14, 2025

LXEO: Motley Fool Moneyball Superscore

56

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lexeo Therapeutics

Lexeo Therapeutics makes medicines that fix heart problems caused by genes. These therapies help people with rare and serious heart conditions. The company works to stop these diseases from getting worse.

Healing Hearts With Genetic Tools

  • LX2006: Investigational gene therapy for cardiomyopathy linked to Friedreich ataxia; currently in a pivotal clinical trial.
  • LX2020: Clinical candidate targeting arrhythmogenic cardiomyopathy caused by specific gene mutations; received Regenerative Medicine Advanced Therapy designation in Aug. 2026.
  • LX1001: Gene therapy candidate for patients with the APOE4 gene associated with Alzheimer's disease.
  • LX1004: Developmental treatment for CLN2 Batten disease, a rare nervous system disorder.

Regulatory Wins and Pipeline Progress

  • Received Breakthrough Therapy designation for LX2006 in July 2025.
  • Entered the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program in July 2025.
  • Initiated the SUNRISE-FA 2 pivotal clinical study in June 2026.
  • Secured Regenerative Medicine Advanced Therapy designation for LX2020 in Aug. 2026.

The Engineering Behind the Medicine

Lexeo utilizes the AAVrh10 vector to deliver genetic material to heart cells with high efficiency. This delivery method allows for lower dosing, which may reduce potential toxicity and bypass existing immunity issues.

Financial Health and Clinical Costs

  • Net loss was $46.1 million for the six-month period ended June 30, 2026.
  • Total cash, cash equivalents, and investments reached $234.2 million as of June 30, 2026.
  • Research and development expenses rose to $19.0 million in the quarter ended June 30, 2026, compared to $14.7 million in the same period of 2025.
  • General and administrative expenses fell to $9.0 million in the quarter ended June 30, 2026, from $16.0 million in the prior-year quarter.

Bottom Line

Lexeo has moved from early research into late-stage clinical testing for its lead heart disease programs. The company maintains a focus on genetic solutions for high-need cardiovascular and neurological conditions.

AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

59

CEO

R. Nolan Townsend, MBA

Website

www.lexeotx.com

Headquarters

New York City, NY 10010, US

LXEO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-41.85%

Return on Capital

-42.92%

Return on Assets

-34.24%

Earnings Yield

-23.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$411.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

82.05M

Volume

1.11M

Avg. Volume

927.88K

Financials (TTM)

Gross Profit

-$546.00K

Operating Income

-$95.12M

EBITDA

-$85.44M

Operating Cash Flow

-$88.37M

Capital Expenditure

-$331.00K

Free Cash Flow

-$88.70M

Cash & ST Invst.

$211.70M

Total Debt

$6.81M

Lexeo Therapeutics Performance Analysis

Lexeo Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 654,000-60.5%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Lexeo Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Lexeo Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.2217.1%
20232023-12-31USD -2.4912.0%
20242024-12-31USD -3.0924.1%
20252025-12-31USD -1.86-39.8%
Lexeo Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3045.0%
Q42025-12-3118.2%
Q12026-03-317.4%
Q22026-06-30-20.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$411.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.97M

N/A

Employees

59

N/A

Net Income

-$25.87M

+0.9%

EBITDA

-$25.78M

-1.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$211.70M

+59.3%

Total Debt

$6.81M

-23.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.15M

-33.8%

Short Term Debt

$2.67M

+0.4%

Return on Assets

-34.24%

N/A

Return on Invested Capital

-39.76%

N/A

Free Cash Flow

-$17.60M

+35.6%

Operating Cash Flow

-$17.60M

+35.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LRMRLarimar Therapeutics, Inc.
$4.05-2.88%
DBVTDBV Technologies S.A.
$14.41-0.76%
VNDAVanda Pharmaceuticals Inc.
$5.44+1.68%
KYTXKyverna Therapeutics, Inc.
$8.64+0.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$227.98+0.09%
INTCIntel
$92.09+0.04%
BITOProShares Trust - ProShares Bitcoin ETF
$10.78+0.02%
ONDSOndas
$8.75+0.06%

Questions About LXEO

What is the current price of Lexeo Therapeutics?

Lexeo Therapeutics is trading at $4.99 per share.

What is the 52-week range for Lexeo Therapeutics?

Over the past 52 weeks, Lexeo Therapeutics has traded between $3.99 and $10.99.

How much debt does Lexeo Therapeutics have?

As of the most recent reporting period, Lexeo Therapeutics reported total debt of $6.81M.

How much cash does Lexeo Therapeutics have on hand?

Lexeo Therapeutics reported $92.83M in cash and cash equivalents in its most recent financial results.

What is Lexeo Therapeutics’s dividend yield?

Lexeo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services